Autism - Pipeline Review, H1 2017

Published: Feb, 2017 | Pages: 125 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Autism - Pipeline Review, H1 2017, provides an overview of the Autism (Central Nervous System) pipeline landscape.

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child's sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Autism - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 3, 1, 15, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Autism - Overview
Autism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Autism - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Aequus Pharmaceuticals Inc
AgeneBio Inc
Anima Biotech Ltd
APeT Holding BV
Avanir Pharmaceuticals Inc
BioCrea GmbH
BioHealthonomics Inc
BrainStorm Cell Therapeutics Inc
Confluence Pharmaceuticals LLC
Coronis NeuroSciences Ltd
Curemark LLC
DRI Biosciences Corp
F. Hoffmann-La Roche Ltd
GW Pharmaceuticals Plc
Heptares Therapeutics Ltd
Immuron Ltd
Intra-Cellular Therapies Inc
Leading BioSciences Inc
MedDay SA
Omeros Corp
OptiNose US Inc
Sumitomo Chemical Co Ltd
Autism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Autism - Drug Profiles
(dextromethorphan + quinidine sulfate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acamprosate calcium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-71441 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-88178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aripiprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-0306 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-AT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Autism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GWP-42006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
histamine dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-14242 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-124E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
L-179 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lumateperone tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lurasidone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MD-1103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
niacinamide CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NurOwn - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxytocin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAM-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Insulin Like Growth Factor 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7314 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-999 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block Chloride Channels for Autism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target GPR63 for Autism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Autism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Autism - Dormant Projects
Autism - Discontinued Products
Autism - Product Development Milestones
Featured News & Press Releases
Sep 22, 2016: Blum Study - A Phase 3 Clinical Trial for Children with Autism
Jul 20, 2016: Immuron to Cooperate with Leading Australian Universities on Autism Research
Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch
Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole
May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism
Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment
Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism
Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors
Aug 06, 2012: Curemark To Enroll Children 9-12 Years Of Age Into Medical Trial Of CM-AT For Children With Autism
May 31, 2012: Study Reports New Treatment For Irritability In Autism
Dec 07, 2011: Curemark Reports Positive Phase III Results Of CM-AT In Children With Autism
Mar 21, 2011: Curemark Completes Enrollment Of Phase III Trials For CM-AT In Autism
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Autism, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Autism - Pipeline by Addex Therapeutics Ltd, H1 2017
Autism - Pipeline by Aequus Pharmaceuticals Inc, H1 2017
Autism - Pipeline by AgeneBio Inc, H1 2017
Autism - Pipeline by Anima Biotech Ltd, H1 2017
Autism - Pipeline by APeT Holding BV, H1 2017
Autism - Pipeline by Avanir Pharmaceuticals Inc, H1 2017
Autism - Pipeline by BioCrea GmbH, H1 2017
Autism - Pipeline by BioHealthonomics Inc, H1 2017
Autism - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017
Autism - Pipeline by Confluence Pharmaceuticals LLC, H1 2017
Autism - Pipeline by Coronis NeuroSciences Ltd, H1 2017
Autism - Pipeline by Curemark LLC, H1 2017
Autism - Pipeline by DRI Biosciences Corp, H1 2017
Autism - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Autism - Pipeline by GW Pharmaceuticals Plc, H1 2017
Autism - Pipeline by Heptares Therapeutics Ltd, H1 2017
Autism - Pipeline by Immuron Ltd, H1 2017
Autism - Pipeline by Intra-Cellular Therapies Inc, H1 2017
Autism - Pipeline by Leading BioSciences Inc, H1 2017
Autism - Pipeline by MedDay SA, H1 2017
Autism - Pipeline by Omeros Corp, H1 2017
Autism - Pipeline by OptiNose US Inc, H1 2017
Autism - Pipeline by Sumitomo Chemical Co Ltd, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Autism - Dormant Projects, H1 2017
Autism - Dormant Projects, H1 2017 (Contd..1), H1 2017
Autism - Discontinued Products, H1 2017